1Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 2Center for Human Immunobiology, Department of Medicine, Feinberg ...
Cancer Res (2025) 85 (18_Supplement_3): B004.
1Centre for Computational Biology, Duke-NUS Medical School, Singapore ...
Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...
Pan-RAS inhibitors have been developed for the treatment of RAS-mutant cancers. Despite the challenges in achieving clinical benefits, targeting Pan-RAS represents a novel strategy for treating these ...
MS Bioworks, LLC, Ann Arbor, MI.
Suzhou Genhouse Pharmaceutical Co., Ltd., Suzhou, China.
Creighton University School of Medicine, Omaha, NE.
Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York ...
University of Arkansas for Medical Sciences, Little Rock, AR.
Applied Quantum Materials Inc., Edmonton, Alberta, Canada.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback